
Akcea cuts 10% of staff following FDA rejection
pharmafile | September 10, 2018 | News story | Manufacturing and Production, Sales and Marketing | Akcea, FDA, Waylivra, pharma
Akcea Therapeutics has been hit hard by the FDA’s decision to reject its drug Waylivra (volanesorsen) for the treatment of familial chylomicronaemia syndrome (FCS), a genetic disease characterised by the accumulation of fat in the blood. The company announced that it had taken the decision to cut its workforce as a result of the ruling.
Akcea received a complete response letter from the US agency last month alerting it to the rejection decision, which is believed to revolve around concerns over platelet declines as a result of Waylivra’s use which forced five participants to discontinue a Phase 3 trial.
As a result, the company confirmed it would be stripping away around 10% of its workforce, cutting down from its current total of 270 in a move “to reorganise its workforce to better align with the immediate needs of its business”.
Akcea has publicly stated that it is working to address the Waylivra’s efficacy concerns with data derived from its ongoing open-label extension study and/or early access programme, and plans to meet the FDA to determine the best path forward.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …





